~~<i id='2441A9F482'><strike id='2441A9F482'><tt id='2441A9F482'><pre id='2441A9F482'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：explore 2025-10-02 19:38:58 - browse：3

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： The most pressing bird flu mysteries scientists want answered

entertainment

focus

leisure time

entertainment

hotspot

JoeRaedle/GettyImagesCouplesinwhichonepartnerisHIV-positivehavealowriskoftransmittingthediseaseifthe

WSS

Sutter Health’s antitrust win overturned by appeals court

STAT wants to know your pick for a great summer read or listen

Sutter Health’s antitrust win overturned by appeals court

CMS got Medicare Advantage quality rating wrong, judge rules

Senators tussle over abortion against the backdrop of a presidential campaign

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

entertainment

explore

entertainment

Affirmative action in medical school literally saved lives

With trial win, GSK could get blood cancer drug back on market

Heart attack and stroke risk calculators need revising

Medicare Advantage's lean provider networks lead CMS complaints

Wildfire smoke exposes gaps in outdoor worker protections

Illumina board agrees to spin off Grail, as divestment plans proceed

Anesthesiologist group: stop taking Ozempic before surgery

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Medicare proposal to cover medical devices draws a mixed reaction

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

focus

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

At ASCO, AstraZeneca reports strong data for breast cancer drug

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Take antibiotics after sex, CDC recommends for certain risk groups

STAT wants to know your pick for a great summer read or listen

focus

leisure time

entertainment

hotspot